<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04568304</url>
  </required_header>
  <id_info>
    <org_study_id>JS001-038-III-UBC</org_study_id>
    <nct_id>NCT04568304</nct_id>
  </id_info>
  <brief_title>A Study Evaluating Toripalimab Injection Combined With Standard Chemotherapy as a First-line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma</brief_title>
  <official_title>A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Study to Evaluate the Efficacy and Safety of Toripalimab Injection (JS001) in Combination With Standard Chemotherapy Versus Placebo in Combination With Standard Chemotherapy as the 1st-line Therapy for Treatment-naive Subjects With PD-L1-positive Locally Advanced or Metastatic Urothelial Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Junshi Bioscience Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Junshi Bioscience Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is being conducted to evaluate the efficacy and safety of Toripalimab Injection in&#xD;
      combination with chemotherapy compared to placebo in combination with chemotherapy in&#xD;
      subjects with PD-L1-positive unresectable locally advanced or metastatic urothelial carcinoma&#xD;
      who have received no previous systemic therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 30, 2020</start_date>
  <completion_date type="Anticipated">November 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Investigator-assessed progression-free survival (INV-PFS) as per RECIST 1.1 criteria</measure>
    <time_frame>Approximately 3 years</time_frame>
    <description>To evaluate the investigator-assessed progression-free survival following Toripalimab Injection in combination with chemotherapy compared to placebo in combination with chemotherapy in subjects with PD-L1-positive unresectable locally advanced or metastatic urothelial carcinoma who have received no previous systemic therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>IRC-PFS</measure>
    <time_frame>Approximately 3 years</time_frame>
    <description>Independent central radiological review committee-assessed progression-free survival as per RECIST1.1 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>INV-ORR, IRC-ORR</measure>
    <time_frame>Approximately 3 years</time_frame>
    <description>Investigator- and IRC-assessed overall response rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>INV-DCR, IRC-DCR</measure>
    <time_frame>Approximately 3 years</time_frame>
    <description>Investigator- and IRC-assessed disease control rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>INV-DoR, IRC- DoR</measure>
    <time_frame>Approximately 3 years</time_frame>
    <description>Investigator- and IRC-assessed duration of response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>Approximately 5 years</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS rate at 1 year</measure>
    <time_frame>Approximately 3 years</time_frame>
    <description>Overall survival rate at 1 year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS rate at 2 years</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Overall survival rate at 2 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>INV-PFS rate and IRC-PFS rate at 6 months</measure>
    <time_frame>Approximately 2.5 years</time_frame>
    <description>Investigator- and IRC-assessed progression-free survival rate at 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>INV-PFS rate and IRC-PFS rate at 1 year</measure>
    <time_frame>Approximately 3 years</time_frame>
    <description>Investigator- and IRC-assessed progression-free survival rate at 1 year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of AEs/SAEs</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Study drug related adverse events, serious adverse events graded in accordance with the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Investigator-assessed PFS</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Investigator-assessed progression-free survival to explore the efficacy of crossover to Toripalimab Injection in control group</description>
  </other_outcome>
  <other_outcome>
    <measure>Investigator-assessed ORR</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Investigator-assessed overall response rate to explore the efficacy of crossover to Toripalimab Injection in control group</description>
  </other_outcome>
  <other_outcome>
    <measure>Investigator-assessed DCR</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Investigator-assessed disease control rate to explore the efficacy of crossover to Toripalimab Injection in control group</description>
  </other_outcome>
  <other_outcome>
    <measure>Investigator-assessed DoR</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Investigator-assessed duration of response to explore the efficacy of crossover to Toripalimab Injection in control group</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">364</enrollment>
  <condition>Locally Advanced or Metastatic Urothelial Carcinoma</condition>
  <arm_group>
    <arm_group_label>Toripalimab Injection + chemotherapy group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + chemotherapy group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Toripalimab Injection</intervention_name>
    <description>Toripalimab Injection 240 mg iv infusion on Day 1 of each 3-week cycle. The cumulative duration of Toripalimab Injection is up to 2 years.</description>
    <arm_group_label>Toripalimab Injection + chemotherapy group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine Hydrochloride for Injection</intervention_name>
    <description>Gemcitabine 1000mg/㎡ iv infusion, on Day 1 and Day 8 of each cycle, each treatment cycle is 3 weeks.&#xD;
The chemotherapy regimen will be administered for 6 cycles.</description>
    <arm_group_label>Placebo + chemotherapy group</arm_group_label>
    <arm_group_label>Toripalimab Injection + chemotherapy group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin for Injection / Carboplatin Injection</intervention_name>
    <description>Cisplatin 70mg/㎡ iv infusion, on Day 1 or Day 2 of each cycle, each treatment cycle is 3 weeks.&#xD;
Carboplatin AUC 4.5 iv infusion, on Day 1 or Day 2 of each cycle, each treatment cycle is 3 weeks.&#xD;
The chemotherapy regimen will be administered for 6 cycles.</description>
    <arm_group_label>Placebo + chemotherapy group</arm_group_label>
    <arm_group_label>Toripalimab Injection + chemotherapy group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo iv infusion on Day 1 of each 3-week cycle. The cumulative duration of placebo is up to 2 years.</description>
    <arm_group_label>Placebo + chemotherapy group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          1. Have full knowledge on this study and are willing to sign informed consent form (ICF);&#xD;
&#xD;
          2. Age 18-75 years at time of signing ICF, male or female;&#xD;
&#xD;
          3. The investigator judged that the subject is eligible for platinum-based chemotherapy;&#xD;
&#xD;
          4. Presence of histopathologically confirmed unresectable locally advanced (T4, any N; or&#xD;
             any T, N2-3) or metastatic urothelial carcinoma;&#xD;
&#xD;
          5. No prior systemic anti-tumor therapy;&#xD;
&#xD;
          6. Subjects who are able to provide tumor tissue slides (≥ 5 slides) for PD-L1 test and&#xD;
             the corresponding pathology report and whose PD-L1 test must be positive before&#xD;
             randomization;&#xD;
&#xD;
          7. With at least one measurable lesion as per RECIST 1.1 criteria;&#xD;
&#xD;
          8. ECOG performance status score of 0-1;&#xD;
&#xD;
          9. Adequate function of vital organs.&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          1. Have received anti-tumor treatments, including chemotherapy, radiotherapy or&#xD;
             investigational product within 28 days before randomization;&#xD;
&#xD;
          2. Have received traditional Chinese medicines with anti-tumor activity or&#xD;
             immunomodulators (eg. Interferon and Interleukin) within 14 days before randomization;&#xD;
&#xD;
          3. Previous use of anti-PD-1/PD-L1 agent or a drug acting on another co-inhibitory T cell&#xD;
             receptor;&#xD;
&#xD;
          4. Subjects who are currently participating in or have participated in a study with&#xD;
             investigational product within 4 weeks before administration;&#xD;
&#xD;
          5. Having received systemic corticosteroid therapy (dose equivalent to prednisone &gt; 10&#xD;
             mg/day) within 14 days before randomization;&#xD;
&#xD;
          6. Subjects with active central nervous system (CNS) metastasis;&#xD;
&#xD;
          7. Grade 2 or higher peripheral neuropathy or hearing loss.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jun Guo, Prof</last_name>
    <phone>86-010-88196348</phone>
    <email>guoj307@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking University Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jun Guo, Prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Zhisong He, Prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yiran Huang, Prof</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 17, 2020</study_first_submitted>
  <study_first_submitted_qc>September 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 29, 2020</study_first_posted>
  <last_update_submitted>September 23, 2020</last_update_submitted>
  <last_update_submitted_qc>September 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

